Who Owns Clariane Company?

Who Owns Clariane?

Understanding Clariane's ownership is key to grasping its strategic moves. In 2024, a significant capital increase aimed to bolster its financial health and support its ongoing development. Clariane, a prominent European provider of elderly and vulnerable care, operates a wide network of facilities.

As of December 31, 2024, Clariane managed 1,220 facilities, offering extensive care services across Europe. The company's financial performance in 2024 showed strong organic growth, with revenues reaching €5,282 million.

Who are the key stakeholders in Clariane's journey? This analysis explores the evolving ownership landscape, from its founders to its public shareholders, and how these relationships impact its strategic direction and governance, including its Clariane BCG Matrix.

Clariane SE was established in 2003, initially known as Korian Medica. While specific founder equity details from its inception are not widely publicized, the company's evolution into a European Company in 2023 included the introduction of an employee shareholding plan, allocating 3% of capital to employees. This early step signaled a commitment to broader stakeholder participation in the company's ownership structure.

Founding Year

Clariane SE was founded in 2003. It began its operations under the name Korian Medica.

Initial Name

The company's original name was Korian Medica. This name was used during its early years of operation.

Employee Shareholding

In 2023, as part of its transformation into a European Company, Clariane implemented an employee shareholding plan. This plan resulted in employees holding 3% of the company's capital.

Public Listing

The company transitioned to public ownership with its listing on Euronext Paris in November 2006. The initial public offering (IPO) price was 34.50 euros per share.

Ownership Transition

The IPO marked a significant shift from its initial private ownership structure. This allowed for broader public investment and a diversification of its shareholder base.

Founder Information

Detailed information regarding the specific equity split among the founders at the company's inception is not readily available in public records.

The journey of Clariane SE, from its founding as Korian Medica in 2003 to its public listing on Euronext Paris in 2006, reflects a strategic progression in its ownership structure. The company's transformation into a European Company in 2023, which included an employee shareholding plan granting employees 3% of the capital, highlights a commitment to inclusive ownership. This move, alongside its earlier IPO at 34.50 euros per share, signifies a diversification of its shareholder base beyond its initial private structure, making it a publicly traded entity. For a deeper understanding of its origins, one can refer to the Brief History of Clariane.

Key Ownership Milestones

Clariane's ownership structure has evolved significantly since its founding. Key milestones include its public listing and the recent implementation of an employee shareholding program.

• Founded in 2003 as Korian Medica.
• Listed on Euronext Paris in November 2006 at 34.50 euros per share.
• Became a European Company in 2023.
• Implemented an employee shareholding plan in 2023, with employees holding 3% of capital.

Complete Clariane Strategy Bundle

• 6 Full Frameworks, 1 Company – All Pre-Researched
• Each Framework Fully Sourced with Real Company Data
• Built for Strategy Courses, Case Studies & MBA Programs
• Adapt to Your Assignment – No Starting from Scratch
• 6 Frameworks: SWOT, PESTLE, Porter's, BMC, BCG and 4P's

GET FULL BUNDLE

Clariane's ownership landscape has seen significant shifts, particularly in 2024, with substantial capital increases impacting its shareholder structure. These events were crucial for the company's financial repositioning.

The company's journey since its initial public offering on November 23, 2006, has been marked by strategic financial maneuvers. As of December 31, 2024, and June 22, 2025, Clariane reported 356,754,459 outstanding shares, each with a nominal value of €0.01. The ownership structure as of the close of 2024 highlights Predica as the principal shareholder, holding approximately 26.00% of the company's shares. Ker Holding (HLD) is another significant stakeholder, with its stake evolving from around 10.45% in mid-2024 to approximately 25.20% by year-end. Flat Footed also maintains a substantial presence, with its ownership hovering around 12.88% to 12.90%. Leima Valeurs holds a 5.60% stake. Notably, retail investors collectively own a considerable 46% of Clariane, indicating a broad base of individual ownership. Institutional investors, on the other hand, represent 10% of the ownership. The collective holdings of the top five shareholders exceed half of the company's total shares, granting them considerable influence over corporate decisions and strategic direction, which is a key aspect of the Growth Strategy of Clariane.

Key Ownership Developments in 2024

Significant capital increases in 2024 reshaped Clariane's ownership. These actions were primarily aimed at bolstering the company's financial health.

• Total capital increases reached approximately €329 million.
• A reserved capital increase of €92.1 million included HLD Europe acquiring a 20.0% stake for €74.1 million.
• A rights offering contributed approximately €237 million to the capital base.
• These measures were designed to reduce debt and strengthen the company's financial structure.

From PESTLE Factors to Full Strategy Bundle

• PESTLE + SWOT + Porter's + BCG + BMC + 4P's in One Bundle
• Every Strategic Angle Covered – Nothing Left to Research
• Pre-filled with Company-Specific Research
• No Missing Sections for Your Case Study
• One Download Covers Your Entire Company Analysis

GET COMPLETE BUNDLE

The Board of Directors for Clariane SE is composed of 15 members, with Sylvia Metayer currently serving as Chair as of May 14, 2025. This composition reflects recent shifts in Clariane company ownership, including representation from significant shareholders like Predica and HLD Europe.

Clariane SE operates under a strict one-share-one-vote principle, ensuring that voting power is directly proportional to share ownership. This structure underpins the decision-making process for the company. The Board is supported by five specialized committees, each focusing on critical areas of corporate governance and strategy. These include the Audit Committee, chaired by Guillaume Bouhours, and the Investment Committee, chaired by Predica. The recent appointment of new institutional directors in 2024 highlights the dynamic nature of Clariane ownership and the commitment to aligning board representation with major investor interests, providing a clear view into who controls Clariane Group.

Clariane's Governance Structure

Clariane SE's governance is managed by a 15-member Board of Directors. This board is supported by five key committees that prepare and study board deliberations.

• Board of Directors: 15 members
• Voting Principle: One-share-one-vote
• Key Committees: Audit, Compensation & HR, Appointments, Investment, Ethics, Quality & CSR
• Recent Board Changes: Reflecting evolving Clariane major investors
• Independent Directors: Ensuring objective oversight

Clariane Business Model + Strategy Bundle

• Ideal for Essays, Case Studies & Slides
• Get BCG, SWOT, PESTLE, Porter's, 4P's Mix & BMC Together
• Company-Specific Content Already Organized
• One Bundle Replaces Days of Independent Research
• Buy the Bundle Once. Use Across All Your Assignments

GET COMPLETE ANALYSIS

In recent years, Clariane has undergone a significant financial restructuring, successfully completing a €1.5 billion plan ahead of schedule by the first half of 2025. This initiative involved substantial capital increases and a targeted disposal program, aimed at strengthening the company's financial foundation and reducing its debt levels.

The company's strategic financial maneuvers have demonstrably improved its leverage position. As of June 30, 2025, the Wholeco leverage ratio stood at 5.6x, a notable decrease from 6.2x recorded in December 2023. This reduction was facilitated by approximately €1 billion in disposals, including the sale of the Petits-fils home care network, executed at an average multiple of around 14x 2024 EBITDA. Further financial enhancements include the successful issuance of a €400 million unsecured bond in June 2025, which saw an oversubscription of more than three times, and the amendment and extension of its syndicated loan facility to May 2029, complemented by a new €150 million real estate credit line. These developments signal a return to more stable funding environments and reflect growing investor confidence in Clariane's trajectory. The company is projecting continued financial deleveraging, with a target Wholeco leverage ratio below 5.5x by the close of 2025. Operationally, Clariane is focused on growth, anticipating organic revenue increases of approximately 5% and EBITDA growth in the range of 6-9% for 2025. Understanding the Revenue Streams & Business Model of Clariane provides further context to these financial developments.

Debt Reduction Efforts

Clariane significantly reduced its net debt through a €1 billion disposal program and capital increases, improving its leverage ratio.

Investor Confidence Boost

The successful issuance of an oversubscribed €400 million bond and loan facility extensions indicate strong market confidence.

Financial Leverage Improvement

The Wholeco leverage ratio decreased to 5.6x by June 2025, with a target of below 5.5x by year-end.

Operational Growth Outlook

The company expects around 5% organic revenue growth and 6-9% EBITDA growth for 2025, driven by operational performance.

From Five Forces to Full Company Analysis

• Includes SWOT, PESTLE, BMC, BCG and 4P's
• Pre-Researched with Company-Specific Data
• Best Value for a Complete Analysis
• Ready to Adapt for Your Case Study
• Ready for Essays and Slidesd

GET FULL BUNDLE